Photobiomodulation therapy, that is, Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese populationb for the recent 3 years with evidence based papers and amazing results. However, there's not yet evidence to demonstrate the relationship between the dose response effect of photobiomodulation therapy on myopia control at the different age lever.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Axial length shortening comparing to that value of baseline (mm）
Timeframe: 12-month
Axial length shortening comparing to that value of baseline (mm）
Timeframe: 1-month
Axial length shortening comparing to that value of baseline (mm）
Timeframe: 6-month